…
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Annexon Inc is a clinical-stage biopharmaceutical company developing therapies that inhibit the classical complement pathway to address neurodegenerative and autoimmune disorders. Long-term growth may be driven by clinical progress across its programs, expansion into additional neurological and immune indications, and partnerships that could extend its platform and appeal to investors seeking exposure to a novel mechanism addressing unmet needs.
Major risks include high dependency on early-stage clinical outcomes, significant regulatory and development uncertainty, no meaningful product revenue requiring additional financing, and competition from other complement and immunomodulatory approaches.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -206.69M | -138.20M | -134.24M | -141.95M | -130.32M |
| Net income | -206.69M | -138.20M | -134.24M | -138.29M | -127.79M |
| Selling general administrative | 31.71M | 34.62M | 28.02M | 33.10M | 30.65M |
| Selling and marketing expenses | - | - | 3.27M | - | - |
| Gross profit | -3.69M | -3.45M | -3.27M | - | - |
| Reconciled depreciation | 2.17M | 2.15M | 2.14M | 2.11M | 2.14M |
| Ebit | -216.41M | -138.20M | -143.72M | -147.71M | -132.85M |
| Ebitda | -213.76M | -134.75M | -141.57M | -145.60M | -130.71M |
| Depreciation and amortization | 2.65M | 3.45M | 2.15M | 2.11M | 2.14M |
| Operating income | -216.41M | -154.07M | -143.72M | -145.60M | -130.71M |
| Other operating expenses | 216.41M | 154.07M | 143.72M | 145.60M | 130.71M |
| Interest expense | - | - | - | 3.65M | 2.14M |
| Tax provision | - | - | - | - | 0.00M |
| Interest income | 9.72M | 15.87M | 9.68M | 3.65M | 0.39M |
| Net interest income | 9.72M | 15.87M | 9.68M | 3.65M | 0.39M |
| Income tax expense | - | - | - | -3.65M | -2.53M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 212.72M | 150.62M | 143.72M | 145.60M | 130.71M |
| Cost of revenue | 3.69M | 3.45M | 3.27M | - | - |
| Total other income expense net | 9.72M | 15.87M | 9.49M | 3.65M | 0.39M |
| Net income from continuing ops | -206.69M | -138.20M | -140.73M | -145.60M | -130.71M |
| Net income applicable to common shares | - | - | - | -141.95M | -130.32M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 277.57M | 350.07M | 297.67M | 285.10M | 287.04M |
| Other current assets | 3.85M | 4.44M | 4.14M | 5.44M | 4.98M |
| Total liab | 65.92M | 56.97M | 47.12M | 53.90M | 55.13M |
| Total stockholder equity | 211.65M | 293.11M | 250.56M | 231.19M | 231.91M |
| Other current liab | 24.79M | 17.57M | 10.28M | 13.63M | 0.14M |
| Common stock | 0.15M | 0.11M | 0.08M | 0.05M | 0.04M |
| Capital stock | 0.15M | 0.11M | 0.08M | 0.05M | 0.04M |
| Retained earnings | -917.39M | -710.70M | -572.50M | -438.26M | -296.31M |
| Other assets | - | - | 0.00M | 1.03M | 1.17M |
| Cash | 162.05M | 49.50M | 225.11M | 140.02M | 74.84M |
| Total current liabilities | 42.63M | 30.51M | 17.93M | 22.36M | 21.74M |
| Current deferred revenue | - | - | - | - | 9.25M |
| Net debt | -135.85M | -20.53M | -193.75M | -107.16M | -40.25M |
| Short term debt | 2.91M | 2.52M | 2.17M | 1.32M | 1.20M |
| Short long term debt total | 26.20M | 28.97M | 31.36M | 32.86M | 34.59M |
| Other stockholder equity | 1128.92M | 1003.68M | 823.03M | 669.78M | 528.37M |
| Property plant equipment | - | - | - | 16.84M | 38.18M |
| Total current assets | 242.19M | 316.46M | 263.86M | 248.10M | 247.69M |
| Net tangible assets | - | - | - | 231.19M | 231.91M |
| Short term investments | 76.29M | 262.52M | 34.61M | 102.64M | 167.87M |
| Accounts payable | 14.93M | 10.43M | 5.49M | 7.42M | 11.15M |
| Accumulated other comprehensive income | -0.03M | 0.01M | -0.05M | -0.37M | -0.18M |
| Common stock total equity | - | - | - | 0.05M | 0.04M |
| Retained earnings total equity | - | - | - | -438.26M | -296.31M |
| Non currrent assets other | 9.58M | 4.27M | 1.03M | 1.03M | 1.17M |
| Non current assets total | 35.38M | 33.61M | 33.81M | 37.00M | 39.35M |
| Capital lease obligations | 26.20M | 28.97M | 31.36M | 32.86M | 34.59M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 190.19M | -218.80M | 29.27M | 64.97M | -86.58M |
| Change to liabilities | - | - | - | 5.93M | 3.86M |
| Total cashflows from investing activities | 190.05M | -218.80M | 70.70M | 58.44M | -88.24M |
| Total cash from financing activities | 108.86M | 161.21M | 135.52M | 122.91M | 1.79M |
| Change to operating activities | - | - | - | 4.03M | -0.57M |
| Net income | -206.69M | -138.20M | -134.24M | -141.95M | -130.32M |
| Change in cash | 112.55M | -175.61M | 85.09M | 65.04M | -192.56M |
| Begin period cash flow | 50.53M | 226.14M | 141.05M | 76.01M | 268.56M |
| End period cash flow | 163.08M | 50.53M | 226.14M | 141.05M | 76.01M |
| Total cash from operating activities | -186.36M | -118.01M | -121.14M | -116.31M | -106.11M |
| Issuance of capital stock | 109.56M | 161.87M | 17.55M | 130.48M | 0.00M |
| Depreciation | 2.17M | 2.15M | 2.15M | 2.11M | 2.14M |
| Dividends paid | 1.86M | - | - | - | - |
| Sale purchase of stock | - | - | - | 121.40M | 1.79M |
| Other cashflows from financing activities | 0.24M | -0.67M | 0.01M | -7.57M | 1.79M |
| Change to netincome | - | - | - | 18.52M | 18.79M |
| Capital expenditures | 0.14M | 0.01M | 0.19M | 6.53M | 1.65M |
| Cash flows other operating | - | - | - | -0.99M | -0.21M |
| Cash and cash equivalents changes | - | - | - | 65.04M | -192.55M |
| Change in working capital | 4.23M | 6.36M | -5.80M | 3.74M | 3.28M |
| Stock based compensation | 16.42M | 19.43M | 18.18M | 18.52M | 16.26M |
| Other non cash items | -2.48M | -7.75M | -1.43M | 1.28M | 1.27M |
| Free cash flow | -186.49M | -118.02M | -121.33M | -122.83M | -107.76M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ANNX Annexon Inc |
-0.11 3.12% |
3.41 | - | - | - | 4.88 | -2.47 |
| NVO Novo Nordisk A/S |
-0.54 1.36% |
38.90 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
520.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.34 0.25% |
923.34 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
1400 Sierra Point Parkway, Brisbane, CA, United States, 94005
650 822 5500
96
| Name | Title | Year Born |
|---|---|---|
| Mr. Douglas Love J.D., Esq. | CEO, Pres & Director | 1968 |
| Dr. Larry C. Mattheakis Ph.D. | Exec. VP & Chief Scientific Officer | 1957 |
| Dr. Ted Yednock Ph.D. | Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 1958 |
| Dr. Arnon Rosenthal Ph.D. | Founder | 1956 |
| Ms. Jennifer Lew | Exec. VP & CFO | 1973 |
| Miriam Mason | Sr. VP of Corp. Communications | NA |
| Mr. Michael Overdorf M.B.A. | Exec. VP & Chief Bus. Officer | 1970 |
| Henk-Andre Kroon M.D. | Sr. VP of Translational Medicine | NA |
| Mirella Villa Del Toro | Sec. | NA |
| Mr. Douglas Love Esq., J.D. | CEO, President & Director | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.